share_log

Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"

Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"

關注Panbela Therapeutics；Roth MKM說：“'益普生食品藥品管理局批准Onivyde用於胰腺癌，而Panbela早些時候針對相同適應症的Sbp-101的1/1b期業績使投資者有理由感到樂觀。”重申買入和25美元的目標價”
Benzinga ·  02/15 03:52

Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"

關注Panbela Therapeutics；Roth MKM說：“'益普生食品藥品管理局批准Onivyde用於胰腺癌，而Panbela早些時候針對相同適應症的Sbp-101的1/1b期業績使投資者有理由感到樂觀。”重申買入和25美元的目標價”

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論